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BehaviorChildrenwith HIV infection are at risk of developmental and behavioural challenges. A systematic review in 2009
set out the extent of delay documented in HIV positive children. This study presents an update and re-analysis.
Full searches were conducted in Medline, Cochrane Database and PsycINFO, from which reviewers selected
abstracts and followed references to provide detailed studies on HIV and cognitive performance in children
under 18 to cover the period 2008–2013. The search generated 21 new studies, 17 of which (81%) report some
form of cognitive delay for HIV positive children compared to controls. Some domains measured seem to be
more affected than others, with mixed evidence on language and executive functioning. The need for more
deﬁnitive control of variables was highlighted by the environmental factors contributing to behavioural and
cognitive outcomes. In conclusion this systematic review conﬁrms the prevalence of cognitive delay in children
with HIV and explores the complexity of the issue. The ﬁndings suggest the need for internationally agreed
monitoring tools and studies which control for known contributing factors. Research for children is needed
with a full understanding of developmental challenges, to point the way forward for effective interventions.
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In adults there is growing understanding of the cognitive effects of HIV
on functioning (Rackstraw, 2011). HIV can cross the blood brain barrier
and permeate the central nervous system quite rapidly after exposure to
the virus (Armstrong, 2006). Guidelines for assessment, diagnosis and
treatment for HIV associated neurocognitive disorders (HAND) (Antinori
et al., 2013) suggest it is appropriate to assess neurocognitive functioning
in all patients with HIV, not just the symptomatic with regular follow up,
speciﬁcally if there is evidence of deterioration or change in clinical status.
There is still no deﬁnitive tool adapted andmade appropriate for children.
Cognitive challenge in adults refers to the loss of cognitive abilities. Cogni-
tive challenge in children refers to the failure to gain cognitive abilities or
to gain this at a different rate to comparison children. These are very differ-
ent concepts.
It is of concern that less attention has been focused on children, as the
effects on a developing infant may differ from a fully grown adult, and in
order to plan for services, interventions, treatment and care, it is important
to understand the cognitive abilities and developmental milestones of HIV
positive children (Le Doaré, Bland, & Newell, 2012). There is a body of
knowledge from the child development literature describingmultiple fac-
tors contributing to cognitive development or developmental delay. Many
of these factors canbe foundwithin families affectedbyHIVandAIDS. Chil-
drenwith HIV are subject to the potential impact of the virus, of antiretro-
viral treatment (ART) and environmental factors that are known to affect1739 hits 
1657 unique hits
to be screened
63 papers to be 
reviewed in full-
text
21 studies in final 
set
7 inaccessible
2 papers from following 
references
Fig. 1. Paper Incluscognitive development. Reduced stimulation is a predictor of poor cogni-
tive performance. In households where poverty and illness occur, parental
responsiveness and environmental richness may be reduced. The docu-
mented risk factors for HIV infection in theﬁrst place are also often record-
ed as risks for cognitive or developmental delay. These include parental
risks such as alcohol, drug use, diagnosedmental health disorders, chronic
family illness and multiple stresses. HIV and AIDS clusters in families, and
many of the burdens, such as stigma, illness, hospitalisation, bereave-
ment, caretaker changes, separation and rejection are well documented
as multiple shocks that such children face. Prematurity is also correlated
with developmental delay, and it is well documented that HIV infection
during pregnancy may elevate premature delivery rates (Townsend
et al., 2010).
A systematic review in 2009 identiﬁed 54 studies cataloguing the cog-
nitive effects of HIV in children (Sherr, Mueller, & Varrall, 2009). The re-
view showed that studies were highly North American biased (66%)
with European studies accounting for 13% and two from South America,
two fromSouth–east Asia and seven fromAfrica (13%),where the vastma-
jority of HIV-infected children reside. The review showed a lack of compa-
rability between studies as a wide array of different cognitive measures
were used. Irrespective of measure used, 81% of studies reported a detri-
mental effect of HIV infection on neurocognitive development forHIV pos-
itive children compared to control groups, whilst three reported no
differences and four had mixed ﬁndings. A more in depth understanding
of various domains of cognitive functioning and how they are affected is37 excluded at full-text screening:
⋅ 8 review
⋅ 2 dissertations
⋅ 26 published before 2008 
⋅ 1 Intervention study 
82 duplicates excluded
1594 excluded from abstract screening:
⋅ 1 books or books chapters
⋅ 1590 not relevant
⋅ 3 Not English
ion Flowchart.
Table 1
Effects of HIV on performance.
Author Study place Sample size (N) Formal measures Domain
measured
Gender Cases and controls HIV detrimental
effect
Abubakar et al.
(2009)
Kenya 367 aged 6–35 months Kiliﬁ Developmental Inventory (KDI) Developmental 178 Males 169
Females
31 HIV+
17 affected
319 control
Yes
Ananworanich et al.
(2008)
Thailand 257 6–16 yrs Child Behaviour Checklist (CBCL) (Thai Version) Behavioural 52% Male 48%
Female
66 HIV+
64 hemat/oncologic
127 control
No
Baillieu and
Potterton (2008)
South Africa 40 aged 18–30 months Bayley Scale of Infant Development, 2nd Edition (BSID-II) Developmental N 40 HIV+ Yes
Baker et al. (2012) USA 70 aged 8–14 yrs The Children's Affective Representations of Relationships Scale (CARRS)
Behaviour Assessment System for Children, Second Edition (BASC-2 SRP)
Peabody Picture Vocabulary Test 3rd Ed (PPVT-III)
The Friendship Quality Questionnaire (FQQ-R)
The Friendship Interview
Behavioural
Cognitive
Social
39 Males 31
Females
21 HIV+
24 affected
25 asthmatic
No
Brackis-Cott et al.
(2009)
USA 325 aged 9–16 yrs Peabody Picture Vocabulary Test Third Edition (PPVT-III)
Reading Subtest of the Wide Range Achievement Test Third Edition (WRAT-3)
Cognitive 161 Males 164
Females
196 HIV+
129 control
Yes
Chernoff et al. (2009) USA 575 aged 6–17 yrs Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV)
The Child and Adolescent Symptom Inventory-4R (CASI-4R)
The Youth's (Self-Report) Inventory (YI-4)
The Child (Self-Report) Inventory-4 (CSI-4)
Behavioural
Cognitive
Mood
285 Males 290
Females
319 HIV+
256 affected
Yes (mixed)
Dobrova-Krol et al.
(2010)
Ukraine 61 mean age
50.9 months
Snijders–Oomen Nonverbal Intelligence Test (SON-R)
Emotional Availability Scales (EAS)
Strange Situation Procedure (SSP)
Cognitive
Social
32 Males
32 Females
29 HIV
35 control
No
Ferguson and Jelsma
(2009)
South Africa 86 aged 1–33 months Bayley Scales of Infant Development 2nd Edition (BSID-II) Developmental N 51 HIV+
35 control
Yes
Gadow et al. (2010) USA and Puerto
Rico
575 aged 6–17 yrs Child and Adolescent Symptom Inventory-4R (CASI-4R)
Youth's (Self-Report) Inventory-4R (YI-4R)
Child (Self-Report) Inventory-4 (CSI-4)
Social and Academic Functioning Questionnaire
Wechsler Intelligence Scale for Children-IV (WISC-IV)
Behavioural
Cognitive
Mood
Social
285 Males, 297
Females
323 HIV+
259 control
Yes (mixed)
Gadow et al. (2012) USA 278 aged 6–17 yrs Child and Adolescent Symptom Inventory (CASI-4R)
Youth Self-Report inventory (YI-4)
Child Self-Report inventory (CSI-4)
Wechsler Intelligence Scale (WISC-IV)
Behavioural
Cognitive
Mood
48% Males 52%
Female
296 HIV+
229 affected
Yes
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Author
Study place Sample size (N) Formal measures Domain measured Gender Cases and
controls
HIV detrimental
effect
Isaranurug and
Chompikul (2009)
Thailand 388 aged 6–12 yrs Standardised Test for Thai Children Cognitive 50.3% Male 49.7%
Female
74 HIV+
223 control
91 unknown HIV
status
Yes (mixed)
Jelsma et al. (2011) South Africa 44 aged 35–74 months Peabody Developmental Motor Scale (PDMS-II) Cognitive
Developmental
24 Males
20 Females
23 HIV+
21 control
Yes
Koekkoek et al.
(2008)
Netherlands 22 medium age 9.46 yrs Revised version of Snijders-Oomen Nonverbal Intelligence Test (SON-R)
Global Intelligence Test
Amsterdam's Neuropsychological Tasks Program tests (ANT)
Verbal Fluency Task
Cognitive 11 Males
11 Females
22 HIV+ Yes
Lowick et al. (2012) South Africa 60 aged 5–6 yrs Grifﬁths Mental Development Scales-Extended Revised Version (GMDS-ER) Developmental 30 Males
30 Females
30 HIV+
30 control
Yes
Maleea et al. (2011) USA and Puerto
Rico
416 aged 7–16 yrs Behaviour Assessment System for Children, 2nd edition (BASC-2) Behavioural 199 Males
217 Females
295 HIV+
121 affected
Yes (mixed)
Mellins et al. (2009) USA 325 aged 9–16 yrs Diagnostic Interview Schedule for Children (DISC-IV) Behavioural
Mood
166 Males
174 Females
196 HIV+
129 control
Yes (mixed)
Rice et al. (2012) USA and Puerto
Rico
437 aged 7–16 yrs Clinical Evaluation of Language Functioning-Fourth Edition (CELF-4) Cognitive 221 Males, 216
Females
284 HIV+
153 affected
No
Serchuck et al.
(2010)
USA & Puerto
Rico
576 aged 6–17 yrs Wong Baker FACES
Short-Form McGill Pain Questionnaire (SF-MPQ)
Symptom Inventory (SI-4)
Cognitive 285 Males 291
Females
320 HIV+
256 affected/control
Yes (mixed)
Thomaidis et al.
(2010)
Greece 60 aged 3–18 yrs The Wechsler Intelligence Scale III (WSCI-III)
Grifﬁths Mental Abilities Scales (GMDS-ER)
Strengths and Difﬁculties Questionnaire (SDQ)
CT/MRI scan
Behavioural
Cognitive
24 Males
36 Females
20 HIV+
40 control
Yes
Van Rie et al. (2008) Democratic
Republic of
Congo
160 aged 18–72 months Bayley Scales of Infant Development 2nd Edition (BSID-II)
Peabody Motor Scales (PDMS-II)
Snijders-Oomen Nonverbal Intelligence (SON)
Rossetti Infant-Toddler Language Scale (RITLS)
Cognitive
Developmental
80 Males
80 Females
35 HIV+
35 affected
90 control
Yes
Van Rie et al. (2009) Democratic
Republic of
Congo
160 aged 18–71 months Bayley Scales of Infant Development 2nd Edition (BSID-II)
Peabody Developmental Motor Scales (2nd Edition) (PDMS-II)
Snijders-Oomen Nonverbal Intelligence Test (SON)
Cognitive
Developmental
80 Males
80 Females
35 HIV+
35 affected
90 control
Yes
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Table 2
Effects of HIV reported in studies.
Study Sample Cognitive measure Score HIV Score HIV affected Score control Score Other P value (HIV + to
controls)
Abubakar et al.
(2009)
Kenya
367 children 6–35 months
(31, HIV+, 17 affected, 319
control)
KDI Psychomotor M = 0.08,
SD = 0.84
M = 0.11,
SD = 0.60
M = −0.91,
SD = 1.86
.05
Locomotor M = 0.06,
SD = 0.84
M = 0.27,
SD = 0.65
M = −0.76,
SD = 1.98
ns
Eye-hand co-ordination M = 0.09,
SD = 0.90
M = -0.10,
SD = 0.65
M = −0.90,
SD = 1.50
.05
Ananworanich
et al. (2008)
Thailand
257 children 6–16 yrs (66
HIV+, 127 control, 64
hematologic/oncologic
diseases)
CBCL ns
Baillieu and
Potterton (2008)
South Africa
40 children 18–30 months
(All HIV+)
BSID (Mental)
Sig delayed
70% Chronological Age Comparison b .001
Mildly delayed 20%
Normal 10%
BSID (Motor) Sig delayed 77.5% b .001
Mildly delayed 10%
Normal 10%
Accelerated 2.5%
Gross Motor Delay 85% b .001
Fine Motor Delay 12.5%
Global Language Delay 82.5%
Baker et al. (2012)
USA
70 children 8–14 yrs (21
HIV+, 24 affected, 25
asthmatic)
CARRS Affect Tone M = 53.62,
SD = 8.46
M = 56.75,
SD = 8.96
M = 50.64,
SD = 9.11
ns (HIV + &
affected)
Emotional Investment M = 52.14,
SD = 4.61
M = 53.88,
SD = 5.91
M = 47.92, SD
9.08
BASC-2 SRP
Interpersonal Relations
M = 50.62,
SD = 9.3
M = 50.29,
SD = 11.73
M = 47.08,
SD = 11.17
Peabody Picture Vocab M = 92.0,
SD = 12.15
M = 92.67,
SD = 8.3
M = 92.16,
SD = 10.66
FQQ-R
Companionship &
Recreation
M = 0.5,
SD = 0.15
M = 0.54,
SD = 0.16
M = 0.38,
SD = 0.19
Validation & Caring M = 3.18,
SD = 0.48
M = 3.45,
SD = 0.54
M = 2.83,
SD = 0.95
Help & Guidance M = 2.78,
SD = 0.72
M = 2.94,
SD = 0.56
M = 2.55,
SD = 0.82
Intimate Disclosure M = 2.09,
SD = 0.96
M = 2.85,
SD = 0.75
M = 2.17,
SD = 1.04
Conﬂict Resolution M = 2.70,
SD = 0.97
M = 3.14,
SD = 0.74
M = 2.60,
SD = 1.01
Conﬂict & Betrayal M = 1.08,
SD = 0.63
M = 0.82,
SD = 0.61
M = 1.05,
SD = 0.69
Brackis-Cott et al.
(2009)
USA
325 children 9–16 yrs (196
HIV+, 129 control)
PPVT-III 83.82
(SD = 14.81)
87.55
(SD = 13.47)
b .05
WRAT-3
Reading
88.23
(SD = 17.92)
93.77 (SD = 17.72 b .05
Chernoff et al.
(2009)
USA
575 children 6–17 yrs
(319 HIV+, 256 affected)
CASI-4R & DSM-IV
Screening Prevalence
Any problems
194(61%) 115(61%) ns
ADHD 56(18%) 42(17%) ns
Aggression 45(14%) 41(16%) ns
Mood 55(17%) 51(20%) ns
Anxiety 119(37%) 111(44%) ns
Impairment
Any problems
46(15%) 35(14%) ns
ADHD 38(12%) 28(11%) ns
Aggression 19(6%) 17(7%) ns
Mood 4(1%) 7(3%) ns
Anxiety 17(5%) 12(5%) ns
Impairment & Screening
Any problems
55(17%) 42(17%) ns
ADHD 37(12%) 28(11%) ns
Aggression 20(6%) 19(8%) ns
Mood 9(3%) 11(4%) ns
Anxiety 9(3%) 11(4%) ns
Dobrova-Krol et al.
(2010)
Ukraine
61 children, mean age
50.9 months (29 HIV+,
32 control)
SON-R
Family reared children
M = 78.00,
SD = 16.87
M = 97.63,
SD = 19.40
b .05
Institution children M = 64.00,
SD = 14.32
M = 67.31,
SD = 18.97
ns
EAS
Family reared children
M = − .19,
SD = 1.34
M = 1.39,
SD = 1.43
b .05
Institution children M = −0.62,
SD = 1.41
M = −0.96,
SD = 1.62
ns
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Table 2 (continued)
Study Sample Cognitive measure Score HIV Score HIV affected Score control Score Other P value (HIV + to
controls)
SSP
Attachment Security
Family reared children
M = 4.63,
SD = 1.31
M = 5.97,
SD = 1.74
b .05
Institution children M = 4.27,
SD = 1.87
M = 3.75,
SD = 1.94
ns
Attachment
Disorganisation
Family reared children
M = 4.14,
SD = 2.30
M = 2.79,
SD = 1.66
ns
Institution children M = 4.00,
SD = 2.34
M = 4.44,
SD = 1.88
ns
Ferguson and
Jelsma (2009)
South Africa
86 age 1–33 mths (51
HIV+, 35 control)
BSID (Motor)
Normal
9.8% 65.7% b .001
Mildly delayed 23.5% 28.6%
Signiﬁcantly delayed 66.6% 5.7%
Gadow et al.
(2010) USA &
Puerto Rico
575 children 6–17 yrs (319
HIV+, 256 control)
CASI-4R
Any disorder
47 (24%) 35 (33%) ns
ADHD 20 (10%) 18 (17%) ns
Oppositional deﬁant 17 (9%) 10 (10%) ns
Conduct disorder 1 (1%) 9 (9%) b .001
Generalised anxiety 19 (10%) 13 (12%) ns
Separation Anxiety 8 (4%) 5 (5%) ns
Depression 13 (7%) 11 (10%) ns
Manic episode 8 (4%) 9 (9%) ns
Caregiver Reported
Social Functioning
M = 1.9,
SD = 1.4
M = 1.9, SD = 1.5 ns
Academic Functioning M = 2.7,
SD = 2.2
M = 2.0, SD = 2.1 b .001
WISC-IV
Working Memory subtest
M = 8.5,
SD = 3.2
M = 8.9, SD = 3.0 ns
Processing Speed subtest M = 8.0,
SD = 3.1
M = 9.4, SD = 3.1 b .001
Gadow et al.
(2012)
USA & Puerto
Rico
278 children 6–17 yrs (157
HIV+, 121 affected)
CASI-4R
Any symptom
Screening cut-off
69% 70% ns
Clinical cut-off 24% 25%
Impairment cut-off 23% 20%
ADHD
Screening cut-off
25% 26% ns
Clinical cut-off 16% 15%
Impairment cut-off 16% 10%
Disruptive Behaviours
Screening cut-off
22% 21% ns
Clinical cut-off 12% 14%
Impairment cut-off 11% 13%
Depression
Screening cut-off
21% 30% ns
Clinical cut-off 6% 10%
Impairment cut-off 4% 5%
Anxiety
Screening cut-off
24% 37% ns
Clinical cut-off 11% 10%
Impairment cut-off 4% 7%
Wechsler Intelligence Scale
Working memory
M = 8.6,
SD = 3.1
M = 8.8, SD = 3.0 ns
Processing Speed M = 8.1,
SD = 3.0
M = 9.4, SD = 3.0 b .001
Isaranurug and
Chompikul
(2009)
Thailand
388 children 6–12 yrs (74
HIV+, 223 control, 91
unknown HIV status)
Standardised Test for Thai
Children
Moral Character
61.0 (10.3) 61.8 (8.9) 62.0 (8.8) ns
Self-control 17.7 (3.4) 18.8 (3.0) 18.1 (3.1) b .05
Sensitive to others 23.7 (5.3) 23.8 (4.7) 24.3 (4.6) ns
Acceptance of criticism 19.6 (4.0) 19.3 (3.7) 19.6 (3.7) ns
Ability 48.5 (7.5) 50.2 (7.3) 49.9 (7.9) ns
Effort 18.3 (3.8) 19.1 (3.7) 19.0 (3.7) ns
Well Adaptation 14.4 (3.0) 14.8 (3.0) 14.8 (3.3) ns
Expressiveness 15.8 (4.5) 16.3 (3.2) 16.1 (3.0) ns
Contentment 49.7 (8.1) 50.1 (9.5) 51.0 (7.8) ns
Self-esteem 15.7 (3.4) 16.0 (3.4) 16.7 (2.9) ns
Quick Recovery 15.7 (3.2) 17.0 (3.2) 16.6 (3.3) b .05
Cheerfulness 18.3 (4.2) 17.0 (5.8) 17.8 (3.8) ns
Overall 159.1 (21.4) 162.1 (21.5) 163.0 (21.4) ns
Jelsma et al. (2011)
South Africa
44 children 35–74 months
(23 HIV, 21 control)
PDMS-II
Fine Motor Quotient
M = 83.8,
SD = 13.2
M = 96.6,
SD = 13.8
b .001
Gross Motor Quotient M = 77.9,
SD = 11.5
M = 96.1,
SD = 11.5
b .001
(continued on next page)
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Table 2 (continued)
Study Sample Cognitive measure Score HIV Score HIV affected Score control Score Other P value (HIV + to
controls)
Total Motor Quotient M = 79.3,
SD = 10.2
M = 95.3,
SD = 11.8
b .001
Koekkoek et al.
(2008)
Amsterdam
22 children medium age
9.46 yrs (All HIV+)
SON-R M = 95.0,
SD = 16.2
ns
Global Intelligence Test
Pattern
Recognition Speed
M = −0.78,
SD = 0.83
b .01
Accuracy M = −0.49,
SD = 0.88
b .05
Tracking Accuracy M = −0.27,
SD = 1.28
ns
Tapping M = 0–0.48,
SD = 1.47
ns
ANT
Pursuit Accuracy
M = −0.18,
SD = 1.18
ns
Shifting Set—Speeds 1 & 2 M = −0.83,
SD = 1.13
b .01
Speed (part 3) M = −1.69,
SD = 1.16
b .01
Accuracy 1 & 2) M = −0.59,
SD = 1.16
b .05
Accuracy (3) M = −0.63,
SD=,1.34
ns
Visuo-spatial Memory
Order irrelevant
M = −1.086,
SD = 1.48
ns
Order relevant M = −1.556,
SD = 1.83
b .05
Verbal Fluency Task M = 0.91,
SD = 0.99
b0.001
Lowick et al.
(2012)
South Africa
60 children 5–6 yrs (30 HIV,
30 control)
GMDS-ER (Means)
General Quotient
70 78.0 b .01
Locomotor domain 75.7 82.7 b .01
Personal-social domain 76.8 85.8 b .01
Hearing-speech domain 60.6 66.9 b .05
Eye-hand domain 77.3 82.8 b .05
Performance domain 62.3 73.1 b .05
Practical-reasoning 68.3 75.4 b .01
Maleea et al.
(2011)
USA & Puerto
Rico
416 children 7–16 yrs (295
HIV, 121 affected)
BASC-2
Behavioural Symptoms
Index
M = 51.5,
SD = 10.2
M = 54.6,
SD = 12.8
BASC-2 norms b .05
Emotional Symptoms
Index
M = 49.1,
SD = 9.3
M = 49.3,
SD = 10.1
ns
Mellins et al.
(2009)
USA
340 children 9–16 yrs (206
HIV, 134 control)
DISC-IV
Any psychiatric disorder
125 (60.7%) 66 (49.3%) b .05
Anxiety disorder 101 (49.0%) 55 (41.0%) ns
Mood Disorder 15 (7.3%) 7 (5.2%) ns
Behavioural Disorder 53 (25.7%) 32 (23.9%) ns
ADHD 37 (18.0%) 11 (8.2%) b .05
Substance Abuse 4 (1.9%) 8 (6.0%) ns
Rice et al. (2012)
USA & Puerto
Rico
437 children 7–16 yrs (284
HIV+, 153 affected)
Clinical Evaluation of
Language Functioning-
Fourth Edition
Primary (N = 48)
29 (10%) 19(12%) ns
Concurrent (N = 105) 67 (24%) 38 (25%)
None (N = 284) 188 (66%) 96 (63%)
Total (N = 437) 284 153
Serchuck et al.
(2010)
USA & Puerto
Rico
576 children 6–17 yrs (320
HIV+, 256 affected/control)
Wong Baker FACES ns
SF-MPQ
Pain In The Last 2 months
130(41%) 82(32%) b .05
Males 34% 31% ns
Females 47% 33% b .05
Pain In The Last 2 Weeks 91(28%) 50(19%) b .05
Males 25% 14% b .05
Females 32% 25% ns
Duration N1 Week 64(20%) 28(11%) b .05
Males 14% 10% ns
Females 26% 11% b .05
Evaluated Odds Pain
Generalised Anxiety
(GAD)
Subject Caregiver
1.07 (b .05)
1.13 (ns)
1.08 (b .05)
1.22 (ns)
Major Depression (MDD)
Subject Caregiver
1.15 (b .05)
1.14 (ns)
1.08 (ns)
1.25 (ns)
Dysthymia (DD)
Subject Caregiver
1.18 (b .05)
1.18 (ns)
1.08 (ns)
1.31 (ns)
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Table 2 (continued)
Study Sample Cognitive measure Score HIV Score HIV affected Score control Score Other P value (HIV + to
controls)
Thomaidis et al.
(2010)
Greece
60 children 3–18 yrs (20
HIV+, 40 control)
NA = Neuroimaging
Abnormality
WISC-III & GMDS General
IQ Score HIV+without NA
M = 58.8,
SD = 11.82
M = 78.0,
SD = 18.2
ns
HIV+ with NA M = 82.4,
SD = 18.8
b .05
Practical IQ Score
HIV+ without NA
M = 85.3,
SD = 22.6
M = 78.5,
SD = 21.6
ns
HIV+ with NA M = 57.6,
SD = 15.0
b .05
Verbal IQ Score
HIV+ without NA
M = 80.5,
SD = 14.9
M = 78.4,
SD = 15.3
ns
HIV+ with NA M = 65.6,
SD = 14.4
ns
SDQ
Emotional HIV+ without
NA
M = 3.4,
SD = 2.3
M = 2.4, SD = 1.7 ns
HIV+ with NA M = 2.2,
SD = 1.1
ns
ConductHIV+without NA M = 1.7,
SD = 1.5
M = 2.0, SD = 1.2 ns
HIV+ with NA M = 2.6,
SD = 0.9
ns
Hyperactivity HIV+
without NA
M = 4.3,
SD = 2.9
M = 3.1, SD = 1.6 ns
HIV+ with NA M = 2.6,
SD = 1.7
ns
Peer problem HIV+
without NA
M = 2.5,
SD = 1.6
M = 2.2, SD = 1.3 ns
HIV+ with NA M = 2.2,
SD = 2.4
ns
Prosocial HIV+ without
NA
M = 8.5,
SD = 1.6
M = 8.3, SD = 1.6 ns
HIV+ with NA M = 8.6,
SD = 1.9
ns
Total score HIV+ without
NA
M = 11.7,
SD = 6.6
M = 9.1, SD = 3.6 ns
HIV+ with NA M = 9.6,
SD = 2.6
ns
Van Rie et al.
(2008)
Democratic
Republic of
Congo
160 children 18–72 months
(35 HIV+, 35 affected, 90
control)
Total No. of ChildrenMental 35 35 90 b .0001
No + Moderate 14(40.0%) 21(60.0%) 68(75.6%)
Severe 21(60.0%) 14 (40.0%) 22(24.4%)
Motor b .0001
No + Mild 25(71.4%) 30(85.7%) 90(100%)
Severe 10(28.6%) 5(14.3%) 0(0.0%)
Children 18–29 months
Mental
11 13 20 b .0001
No + Moderate 1(9.0%) 9(69.2%) 17(85.0%)
Severe 10(90.9%) 4(30.8%) 3(15.0%)
Motor b .0001
No + Mild 2(18.2%) 8(61.5%) 20(100.0%)
Severe 9(81.8%) 5(38.5%) 0(0.0%)
Children 30–72 months
Mental
24 22 70 ns
No + Moderate 13(54.2%) 12(54.5%) 51(72.9%)
Severe 11(45.8%) 10(45.5%) 19(27.1%)
Motor b .0001
No + Mild 23(95.8%) 22(100.0%) 70(100.0%)
Severely Delayed 1(4.2%) 0(0.0%) 0(0.0%)
Concurrent (N = 105) 67 (24%) 38 (25%)
None (N = 284) 188 (66%) 96 (63%)
Total (N = 437) 284 153
Van Rie et al.
(2009)
Democratic
Republic of
Congo
160 children 18–71 months
(35 HIV+, 35 affected, 90
control)
BSID, PDMS, SON
Cognitive Development
Visit 1 (baseline)
M = 65.8 ± 6.0 M = 74.8 ± 6.0 M = 84.6 ± 3.8 b .0001
Visit 2 (6 months) M = 75.8 ± 6.0 M = 74.9 ± 5.6 M = 87.3 ± 3.8 b .01
Visit 3 (12 months) M = 84.3 ± 7.2 M = 87.6 ± 6.6 M = 96.5 ± 5.0 b .01
Mean Change of 1 to 2 M = 10.0 ± 5.7 M = 0.1 ± 5.2 M = 2.6 ± 3.6 ns
Mean Change of 1 to 3 M = 18.5 ± 7.7 M = 12.8 ± 5.2 M = 11.8 ± 5.2 ns
Motor Development Visit 1
(baseline)
M = 75.7 ± 4.2 M = 87.2 ± 4.2 M = 97.8 ± 2.6 b .0001
Visit 2 (6 months) M = 82.4 ± 4.0 M = 91.0 ± 3.8 M = 101.0 ± 2.6 b .0001
Visit 3 (12 months) M = 90.4 ± 3.8 M = 94.0 ± 3.6 M = 105.0 ± 2.6 b .0001
Mean change of 1 to 2 M = 6.7 ± 3.8 M = 3.8 ± 3.6 M = 2.7 ± 2.4 ns
Mean Change of 1 to 3 M = 14.6 ± 4.2 M = 6.8 ± 3.8 M = 7.6 ± 2.8 b .01
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and roll out of antiretroviral treatment as well as advances in identifying
children and providing paediatric compounds. Even though treatment
roll out to children may be lagging, it is unclear to what extent (if any)
antiretroviral treatment itself affects cognitive outcome. Comparisons be-
tween children on treatment and those not yet receiving treatment may
be needed, but clearly treatment decisions as well as compound choice
are driven by medical need. Child development may be affected by many
factors, including parental wellbeing, parental survival, parental employ-
ment, economic situation, parental mental health and level
of stimulation within the home. There may well be a complex effect
of HIV on some or all of these factors which can speciﬁcally affect
the environment and thereby the cognitive development of children
with HIV.
Given these changes, an updated review was conducted to explore
developmental effects of HIV including cognitive, behavioural, develop-
mental and psychological function as measured by the various studies
and standardised child developmental inventories. The review covers
studies on effects of HIV for the period 2008 to 2013. The review also
aims to provide a more detailed understanding of concepts under the
cognitive development umbrella such as language development,
motor skills, memory, executive function, spatial abilities, information
processing and other cognitive processes that would affect how a
child gains access to their learning curriculum and functions in the
emerging adult world.
2. Method
In January 2013 we searched the online databases of Medline,
PubMed, PsycINFO, the Cochrane database and follow up references.
Search terms were informed by the initial systematic review (Sherr
et al., 2009). Search terms were varied to adapt to the requirements of
the different databases. The search terms included HIV, child, various
forms of child (such as infant, minor, baby new-born), cognitive, psy-
chosocial, emotional development, neurological function, intellectual
learning language or memory and explored control and comparison
group provision (see Appendix A for speciﬁc search criteria and number
of results at each stage). The aimwas to abstract data from the studies of
competent design, to track the level of neurocognitive development ef-
fect, to explore measurement tools used, to log demographic variables
in terms of study sites, to examine whether different domains of func-
tioning are studied and to consider the nature and quality of comparison
and control groups in order to establish causal pathways in terms of HIV
infection on cognitive development.
2.1. Inclusion and exclusion criteria
Papers were restricted to English language publications and were
included if they provided empirical data on HIV infected children
with a control or comparison group—either HIV exposed but unin-
fected children (affected) or uninfected unexposed controls. To
meet inclusion criteria studies had to report a cognitive, develop-
mental or mental health measurement for both groups. Non primary
data, review articles and opinion pieces were excluded. After the
searchwas conducted, paperswere read by a teamof three psychologists
for conﬁrmation of inclusion. The lead author took responsibility for
adjudication in cases of non-agreement. The search was conducted
in line with the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) recommendations which sets out
design and study characteristics for grading of quality (CRD, 2009).
The details of the papers were extracted and entered into common
tables listing the full reference, the country of study, the method,
population and group details, listing of eachmeasure andmain ﬁndings
were contrasted for the HIV infected group compared to various
comparison groups. Due to the heterogeneity in the studies, different
methods and the use of a wide range of inventories to measurecomponents of cognitive or developmental parameters, we were not
able to combine results into a meta-analysis.
The search (see Fig. 1) generated 1739 hits. After excluding dupli-
cates and non-relevant items (books and non-English articles) 1657
remained for more detailed exploration of full title and abstract of
which 1594 were excluded on abstract screening as not eligible or
not relevant to the topic under study. The remaining 63 papers
were read in full, except for 7 that were inaccessible. References
from these papers were followed up, generating a further 2 papers
for full text reading. From this phase, 11 were excluded on the
grounds of inadequate or irrelevant data, no HIV infected group, no
control group or no cognitive/psychological functioning outcomes
and 1 was an intervention study. Of the remaining papers, 26 were
excluded as they were originally published before 2008. Twenty-
one published studies were included and were subjected to detailed
data abstraction.
3. Results
3.1. Study characteristics
The highest percentage of datawas fromAfrica (7 studies; 33%)with
24% from the USA, 19% Puerto Rico, 10% Europe (Ukraine, n = 1,
Holland, n=1, Greece, n=1) and 10% fromAsia. The studies character-
istics are set out in Table 1 below. The table provides the study, place,
sample characteristics and measures used. Findings are then coded for
each study into 3 categories, “nodifferences reported, detrimental effect
of HIV reported and mixed ﬁndings”.
Of the 21 studies, 5 compared HIV positive children with those
who had been born to an established HIV positive mother but were
virus free and HIV negative themselves (referred to as “seroreverters”
or HIV affected). Four compared HIV positive childrenwith HIV affected
as well as including a second, HIV negative control—namely children
who had not been exposed to HIV in utero. Eight studies compared
HIV positive children with a negative control group and 2 compared
HIV positive with a control group and other illnesses such as asthma
and hematologic/oncological diseases. These studies were able,
therefore, to control for HIV virus as well as exposure to HIV in utero
and living with an HIV positive mother. Two studies compared HIV
positive children with ‘normative means’. Overall the studies report
on 4237 children; 2023 HIV positive, 727 HIV negative but exposed in
utero, 1307 control unexposed and uninfected children, 91 status
unknown and 89 with other illnesses) (see Table 2).
The age ranges in the studies were varied from infants (one
month) to 18 year olds. Two studies provided no exact detail on
age ranges; they did however provide a mean or median age. The
age ranges make comparisons difﬁcult, due to the fact that there
are different abilities and measures across the different ages and
very few measures are standardised across age groups. Over half
the studies (12/21) sampled children between the age ranges of
5–18 years, with various inclusion ages. Six (6/21) studies included
children between 6 and 17 years; two included 7–16 year old chil-
dren, one was conﬁned to 5–6 year olds, two included 9–16 year
olds, one 8–14 year olds and one 3–18 year olds. Fewer studies in-
cluded children from younger age bands. Three studies included
children as young as 18 months, one included children from
1 month and one included children as young as 6 months old. On
the whole the data is mostly available for older children with
considerable gaps in the early crucial age bands.
3.2. Measurement tools used
There are a wide range of tools available to measure different com-
ponents of cognitive performance. These vary in the design, content
and validation in different cultures. The measurement scales used are
listed in Table 3. This review shows that across the 21 studies, 31 different
Table 3
Standardised scales and measures utilised in studies.
Measures Occasions used
1. Amsterdam's Neuropsychological Tasks (ANT) Program tests 1
2. Bayley Scales of Infant Development 2nd Edition (BSID-II) 4
3. Behaviour Assessment System for Children, 2nd edition (BASC-2) 2
4. Social and Academic Functioning Questionnaire 1
5. Child and Adolescent Symptom Inventory (CASI) 3
6. Child Behaviour Checklist (CBCL) (Thai Version) 1
7. Child Self-Report inventory (CSI) 3
8. Clinical Evaluation of Language Functioning-Fourth Edition
(CELF-4)
1
9. CT/MRI scan 1
10. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 1
11. Diagnostic Interview Schedule for Children (DISC-IV) 1
12. Emotional Availability Scales (EAS) 1
13. Global Intelligence Test 1
14. Grifﬁths Mental Development Scales (GMDS) 2
15. Kiliﬁ Developmental Inventory (KDI) 1
16. Peabody Test, Third Edition (PDMS-III) 5
17. Rossetti Infant–Toddler Language Scale (RITLS) 1
18. Short-Form McGill Pain Questionnaire (SF-MPQ) 1
19. Snijders–Oomen Nonverbal Intelligence Test (SON-R) 4
20. Standardised Test for Thai Children 1
21. Strange Situation Procedure (SSP) 1
22. Strengths and Difﬁculties Questionnaire (SDQ) 1
23. Symptom Inventory (SI-4) 1
24. The Children's Affective Representations of Relationships Scale
(CARRS)
2
25. The Friendship Interview 1
26. The Friendship Quality Questionnaire (FQQ-R) 1
27. Verbal Fluency Task 1
28. Wide Range Achievement Test, Third Edition (WRAT-3) 1
29. Wong Baker FACES 1
30. Wechsler Intelligence Scale (WISC) 5
31. Youth Self-Report inventory (YI) 3
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multiple measures. The Bayley Scales of Infant Development (BSID)
(Bayley, 1993) were used in 4 studies (19%). Other scales used included
the Snijders–Oomen Nonverbal Intelligence Test (SON; Tellegen, Winkel,
Wijnberg-Williams, & Laros, 1998), the Wide Range Achievement Test
(WRAT; Jastak & Jastak, 1965), the Wechsler Scales (WISC; Wechsler,
1991; Kaplan, Fein, Maerlander, Morris, & Kramer, 2004), The Child Behav-
iour Checklist (CBCL Thai version; Achenbach & Rufﬂe, 2000), the Grifﬁths
Scales (GMDS; Grifﬁths, 1970) and Rossetti Infant–Toddler Language Scale
(RITLS; Rossetti, 1990). These were supplemented by an array of function-
ing tests, standardised neurological examinations e.g. CT/MRI scans, school
measurements such as the caregiver completed social and academic func-
tioning questionnaire (Gadow, DeVincent, & Schneider, 2008) and anthro-
pometric measures such as weight, height, and head circumference which
reﬂect on development in terms of growth.
3.3. Human immunodeﬁciency virus and neurocognitive development
Themajority of the studies (17/21) (80.1%) showed that HIVwas as-
sociated with some form of detrimental effect on cognitive develop-
ment, across a wide range of different measures. Eight studies (38%)
reported detrimental effects on all measures and a further 10 (totalling
48%) reported detrimental effects on at least one measure. Of these
eight, seven emanated from Sub-Saharan Africa. Only three studies
found no signiﬁcant differences or effects of HIV between the HIV posi-
tive group and a comparison group (14%). The data from each measure
on the 21 studies are summarised in Table 2.
3.3.1. Language
Seven studies provided speciﬁc data on language scores. Baker, Niec,
andMeade (2012) and Brackis-Cott, Kang, Dolezal, Abrams, andMellins
(2009) used the Peabody Picture Vocabulary test (PPVT; Dunn & Dunn,
1965). Most studies were conducted in the USA: Baker et al. (2012)compared 70 positive, exposed and asthmatic 8–14 year old children
whereas Brackis-Cott et al. (2009) compared 325 HIV positive and neg-
ative 9–16 year old children. Koekkoek, De Sonneville, Wolfs, Licht, and
Geelen (2008) used the verbal ﬂuency sub test of the SON on 22 HIV
positive children with a median age of 9.46 in Amsterdam comparing
them to “norms”. There were no signiﬁcant language differences on
the Baker et al. (2012) study, but the other two studies found signiﬁ-
cantly lower language scores for the HIV positive children. Rice et al.
(2012) carried out a comprehensive language assessment linking this
with hearing impairment and environmental variables on 437 HIV pos-
itive and affected 7–16 year old children in the USA and Puerto Rico.
They found elevated language impairment among both HIV positive
and HIV affected children (40% prevalence rate which is much higher
than the 16% expected rate based on country norms).
3.3.2. Cognitive/executive functioning categories
Only one study explored pattern recognition as a speciﬁc sub-item
(Koekkoek et al., 2008) and found HIV positive children signiﬁcantly
lower in both speed and accuracy than “norms”. Executive function is usu-
ally measured by attention variables, visuo-spatial abilities and working
memory. Koekkoek et al. (2008) found that executive functioning and pro-
cessing speed were speciﬁcally challenged for HIV positive children.
3.3.3. Measure of global development (mental and motor)
Themainmeasure of global developmentwas the BSID. These scales
generate a motor and a mental development score. However, different
researchers utilised the scores differently to examine relative perfor-
mance, proportion that were delayed or proportion with signiﬁcant
delay. Van Rie, Dow, Mupuala, and Stewart (2009) studied 160 18–
71 month old children in the Democratic Republic of Congo (DCR)
with baseline and two follow up measures and showed that the HIV
positive children had lower mean scores than both control groups
(HIV affected and HIV unaffected) at all three time points for both
motor and mental development. Van Rie, Mupuala, and Dow (2008),
appearing to use the same sample as Van Rie et al. (2009), explored
the severity of delay in a study of 160 children (35 HIV positive, 35
HIV affected and 90 controls) who were clustered into three age
bands (18–72 months; 18–29 months and 30–72 months). They
found signiﬁcantly more HIV positive children were severely delayed
(60% versus 40% in the affected group and 24.4% in the control group)
onmental development in the ﬁrst age group. The patternwas repeated
for motor delay with 28.6% of the HIV positive children delayed com-
pared to 14.3% of the affected children and none of the control children.
Of interest was that the differences seemed to dissipate over the time
periods (signiﬁcantly worse at the second time period, but a trend at
the third). Baillieu and Potterton (2008) studied 40 18–30 month old
HIV positive children in South Africa and found signiﬁcantly lower cog-
nitive development than the children's cognitive development for their
chronological age in 97.5% of the sample. Ferguson and Jelsma (2009)
studied 86 1–33 month old HIV positive and healthy children in South
Africa (51 HIV positive, 5 affected and 20 HIV status unknown) and
found that signiﬁcantly more HIV positive children were “signiﬁcantly
delayed” compared to the healthy children (66.6% versus 5.7%).
3.3.4. Behavioural challenges
These weremeasured in diverse ways across the studies. Baker et al.
(2012) showed lowered mean scores on the children's affective repre-
sentation of relationship scale (CARRS; Baker & Niec, 2007) as well as
the emotional investment and the behavioural assessment system for
children (BASC; Reynolds & Kamphaus, 2004) compared to control chil-
dren, but none of these measures reached statistical signiﬁcance. Simi-
larly Ananworanich, Jupimai, Mekmullica, Sosothikul, and Pancharoen
(2008) did notﬁnd any differences on elements of the CBCL Thai version
which examines internal and external behaviours. Ananworanich et al.
(2008) study involved 257 primary caregivers of 6–16 years old HIV
positive, HIV negative and children with hematologic/oncologic
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388 6–12 years old Thai children (74 infected, 223 not infected and 91
status unknown) that there were no differences on sensitivity to others,
acceptance of criticism, adaptation, expressiveness, self-esteem or
cheerfulness but the HIV positive children had signiﬁcantly lower self-
control and quick recovery. Chernoff et al. (2009) also showed, with
557 HIV positive or exposed/living with someone with HIV American
children aged 6–17, no signiﬁcant overall mood problems on items
such as ADHD, aggression or anxiety. The authors also found they had
equal prevalence of psychiatric symptoms, but that the HIV positive
were more likely to receive medication and behavioural treatment.
Baker et al. (2012) also compared children with asthma to those with
HIV on measures of social functioning and friendship quality and
found the HIV positive children to have better outcomes which they at-
tributed to comprehensive multidisciplinary services and support
which buffer against stressors and may in fact facilitate positive out-
comes. This USA study may set a precedent for service provision needs
in other geographical regions.
3.3.5. Gender
Nineteen of the 21 studies (90%) provided data on distribution of
child gender (see Table 1); however, only 6 studies (29%) proceeded
to analyse by gender. Maleea et al. (2011) compared 416 7–16 year
old children (295 HIV positive perinatally infected, 121 affected) in
theUnited States and Puerto Rico onmental health functioning. No gen-
der differences emerged on either the Behavioural Symptoms Index
(BSI) or Emotional Symptoms Index (ESI) (BASC; Reynolds &
Kamphaus, 2004) for the entire group. Gender differences were found
when results were stratiﬁed by infection. HIV affected males were
more likely than females to have elevated BSI scores (37% versus 18%)
and HIV positive females were more likely than HIV positive males to
have elevated ESI scores (18% versus 5.9%). Serchuck et al. (2010) com-
pared 576 6–17 year old children (320 HIV positive, 256 HIV negative)
in the United States and Puerto Rico on the prevalence of pain and psy-
chiatric symptoms. Amongmales, there was a higher prevalence of pain
during the last two weeks for HIV infected than controls (25% vs 14%).
HIV positive females had signiﬁcantly higher rates of pain compared
to control females during the last twomonths (46% vs 33%) and a higher
proportion with pain of more than one-week duration (26% more vs
11%). Baker et al. (2012) found across their entire sample (HIV positive,
control and asthmatic children), girls scored signiﬁcantly higher
than boys on the emotional investment in relationships scale (CARRS)
(M = 54.05, SD = 1.27; M = 48.98, SD = 1.09 respectively). Gadow
et al. (2012) compared 573 6–17 year old children (296 HIV positive
perinatally infected, 229 affected/living with HIV positive person) in
the United States and Puerto Rico on emerging mental health concerns.
They found that across both groups the odds of emerging depression
(OR2.13 (CI 1.16, 3.91)) and anxiety (OR 2.34 (CI 1.26, 4.38)) symptoms
occurring in females were higher than males. Rice et al. (2012) found
within their 7–16 years old HIV positive group, males or children who
had a biological parent as caregiver had signiﬁcantly lower odds of
having a language impairment as well as a cognitive or hearing
impairment. Ananworanich et al. (2008) found that in their sample of
6–16 years old Thai children females had more delinquency problems
than males (p = .007) across the entire sample (HIV positive children,
control children and children with haematologic/oncologic diseases).
3.3.6. Effects of treatment
Very few studies examined the effect of treatment on cognitive out-
come. Koekkoek et al. (2008) noted that higher CD4 count at initiation
of HAART and duration of such treatmentwere both associatedwith im-
proved working memory function and attention control. Four of the
studies (19%) speciﬁed whether any of the mothers were on treatment
while they were pregnant (see Table 4). Forty-one percent of the
mothers were receiving treatment in Rice et al. (2012) study in the
United States and Puerto Rico whereas only 24.5% of mothers were ontreatment in Maleea et al. (2011) study also in the US and Puerto Rico.
Ferguson and Jelsma (2009) showed 18% of the children in the HIV pos-
itive sample had been exposed to PMTCT prophylaxis whilst in utero.
None of the HIV positive mothers were receiving treatment in Van Rie
et al. (2009) study. Only 3 studies (14%) did not state whether the HIV
positive children were receiving antiretroviral treatment. Another 3
studies included HIV positive children who were not receiving treat-
ment: 1 to 33 month old children in South Africa (Baillieu & Potterton,
2008), 6–13 month old children in Kenya (Abubakar, Holding,
Newton, Van Baar, & Van de Vijver, 2009) and 18–72 month old chil-
dren in the Democratic Republic of the Congo (Van Rie et al., 2008).
All the other studies included HIV positive children receiving treatment
ranging from 66.6% in South Africa (Ferguson & Jelsma, 2009) to 100%
(Baker et al., 2012; Jelsma, Davids, & Ferguson, 2011; Lowick, Sawry, &
Meyers, 2012; Thomaidis et al., 2010). Two of the studies, with all the
HIV positive children receiving antiretroviral treatment, were from
South Africa (Jelsma et al., 2011; Lowick et al., 2012), one was from
Greece (Thomaidis et al., 2010) and one was in the United States
(Baker et al., 2012).
3.3.7. Cognitive delay is not universal
Fifteen of the studies presented results which showed how many
HIV positive children did not have any cognitive effects (see Table 4).
Six studies found, on at least one measure, the percentage of children
not affected was 10% or less. Baillieu and Potterton (2008) found only
2.8% of HIV positive children in their sample had a cognitive develop-
mental age not lower than the chronologically age of the sample. Only
9.8% of the HIV positive children from South Africa in Ferguson and
Jelsma's (2009) study had motor performances within the normal
limit. Of the children who received antiretroviral treatment (34 chil-
dren) only 8.82% had a motor performance within the normal limit.
No females aged 12–16 in Ananworanich et al.'s (2008) study were in
the normal range for the CBCL Thai version although all of themale par-
ticipants were. None of the male participants aged 12–16 had a normal
score on the somatic variable of the CBCL whereas 50% of the female
participants did. Lowick et al. (2012) found, in their study in South
Africa, only 3 children overall (10%) were in the total normal range
using the GMDS (Grifﬁths, 1970). Over 70% of the children were in the
normal range for the social-personal domain and over 50% had no deﬁ-
cits in the locomotor domain. Thomaidis et al. (2010) found, in a sample
of 3–18 year olds in Greece, 0 of the 5 HIV positive childrenwith neuro-
imaging abnormalities (NA) had a normal general, practical or verbal IQ
score whereas 40%, 33.3% and 40% of the HIV positive children without
NA had a normal score respectively. Van Rie et al. (2008) found for the
HIV positive children aged 18–29 months 0% had no mental develop-
mental delay and only 9% (one child) had no motor developmental
delay. Children aged 30–72 months had higher levels of children not
having mental or motor delay: 20.8% and 41.7% respectively. All chil-
dren were preschool aged children from the DRC.
Nine studies found, on at least one measure, the percentage of chil-
drenwith no cognitive deﬁcits to be 80% or greater. Three of these stud-
ies found 10%or less of children to be in the normal range on at least one
measure (Ananworanich et al., 2008; Baillieu & Potterton, 2008;
Thomaidis et al., 2010) highlighting HIV may be affecting speciﬁc sub-
domains. Baillieu and Potterton (2008) found no ﬁne motor delay in
87.5% of their sample. Thomaidis et al. (2010) found that 80% or more
of the HIV positive children, both with and without neuroimaging
abnormalities, were in the normal range for emotional, conduct, peer
problems, prosocial scales and the total score on the Strengths and
Difﬁculties Questionnaire (SDQ; Goodman, 1997). Only theHIV positive
children with neuroimaging abnormalities were in the normal range
for the hyperactivity scale on the SDQ. Ananworanich et al. (2008)
found that 80% or more of male and females aged 6–11 were in the
normal range for anxiety, depression, delinquency, hyperactivity
and aggressiveness scales on the CBCL. Eighty-seven percent of the
females were also in the normal range on the social withdrawal
Table 4
Antiretroviral treatment (mother and child) and children with no delay.
Study Mother on treatment Child on treatment No. of children with no cognitive delay
Abubakar et al. (2009) Not given N Only mean scores given
Ananworanich et al. (2008) Not given Not given 6–11 year olds
CBCLM 45% F 61% normal score; AnxietyM 90% F 94% normal score SomaticM 45%
F 52% normal score DepressionM 87% F 94% normal Social WithdrawalMNA F 87%
normal External %—ImmaturityM52%normal score FNADelinquencyM97%F84%normal
HyperactivityM87% F90% normal AggressiveM 97% F 94% normal
12–16 year olds
CBCLM& F 100% normal score AnxietyM& F 100% normal score
SomaticM 0% F 50% normal score Social WithdrawalM& F 100%
ImmaturityM 50% normal score DelinquencyM& F 50% normal
AggressiveM 50% F 100% normal score
Baillieu and Potterton (2008) Not given N-antiretroviral therapy naıve No gross motor delay in 15%; No ﬁne motor delay in 87.5%
No global language delay in 17.5%; Cognitive developmental age not lower than
chronological age in 2.5%
Baker et al. (2012) Not given Y-21 children on antiretroviral
medication (100%)
Only mean scores given
Brackis-Cott et al. (2009) Not given Y-84% on HAART 38%not belowaverage language receptive ability score. 46%didnot score belowaverage
on word recognition. 63% not kept in school.
Chernoff et al. (2009) Not given Y-81% on HAART Screening prevalence (assessed by child or caregiver)
125 (39%) did not meet criteria for any problems
263 (82%) did not meet criteria for ADHD
274 (86%) did not meet criteria for aggression
264 (83%) did not meet criteria for mood disorder
200 (63%) did not meet criteria for anxiety disorder
Impairment (assessed by caregiver)
273 (85%) did not meet criteria for any problems
281 (88%) did not meet criteria for ADHD
300 (94%) did not meet criteria for aggression
315 (99%) did not meet criteria for mood disorder
302 (95%) did not meet criteria for anxiety disorder
Impairment and screening prevalence (assessed by child or caregiver)
264 (83%) did not meet criteria for any problems
282 (88%) did not meet criteria for ADHD
299 (94%) did not meet criteria for aggression
310 (97%) did not meet criteria for mood disorder
310 (97%) did not meet criteria for anxiety disorder
Dobrova-Krol et al. (2010) Not given Y-18/20 received the same
anti-retroviral medications.
In the HIV infected group, 44% of family-reared children were found to demonstrate
secure attachment. For HIV-infected institution-reared children: 31% were found to
demonstrate secure attachment.
Only mean scores given for the rest of results
Ferguson and Jelsma (2009) Y – 18% Y-34 (66.6%) on ART 9.8% had motor performance within normal limits.
Of those receiving ART (n = 34), 8.82% hadmotor performancewithin normal limits.
Of those HIV infected children exposed to antiretroviral prophylaxis (n = 20), 10%
had motor performance within normal limits.
Of the participants on ART for b6 months (n = 17), 5.88% had motor performance
within normal limits and of those on ART N6 months (n = 17) 11.76% had motor
performance within normal limits.
Gadow et al. (2010) Not given Y-(66%) highly active
antiretroviral treatment
(HAART) with protease
inhibitors, and 15% HAART
without PI
88% did not meet criteria for attention-deﬁcit/hyperactivity disorder
95% did not meet criteria for oppositional deﬁant disorder
99% did not meet criteria for conduct disorder
98% did not meet criteria for generalised anxiety disorder
99% did not meet criteria for separation anxiety disorder
98% did not meet criteria for depressive disorder
99% did not meet criteria for manic episode
No psychotropic meds (ever) N = 245; 77% (current)N = 276; 87%
No behavioural therapy (ever) N = 235; 73%
No therapy (ever) N = 203; 63%
No special education (ever evaluated for) N = 183; 56%
Gadow et al. (2012) Not given Not given 31% no Symptom Cutoff score for at least 1 targeted disorder.
Any disorder—31% did not meet criteria at screening cutoff
76% did not meet criteria at clinical cutoff
77% did not meet criteria at impairment cutoff
ADHD—75% did not meet criteria at screening cutoff
84% did not meet criteria at clinical cutoff
84% did not meet criteria at impairment cutoff
Disruptive behaviours—78% did not meet criteria at screening cutoff
88% did not meet criteria at clinical cutoff
89% did not meet criteria at impairment cutoff
Depression—79% did not meet criteria at screening cutoff
96% did not meet criteria at clinical cutoff
94% did not meet criteria at impairment cutoff
Anxiety—76% did not meet criteria at screening cutoff
89% did not meet criteria at clinical cutoff
96% did not meet criteria at impairment cutoff
Isaranurug and Chompikul (2009) Not given Not given Only mean scores given
(continued on next page)
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Table 4 (continued)
Study Mother on treatment Child on treatment No. of children with no cognitive delay
Jelsma et al. (2011) Not given Y-100% (23 children) Only mean scores given
Koekkoek et al. (2008) Not given Y-18 HAART and 2 new
commenced
Only mean scores given
Lowick et al. (2012) Not given Y-30 HIV-infected preschool
children (stable on ART for
more than one year) (100%)
Total overall N = 3, 10%; Locomotor domain N = 16, 53.3%
Personal-social domain N = 22, 73.3%; Hearing-speech domain N = 3, 10%; Eye-
hand domain N = 15, 50%; Performance domain N = 11, 36.7%; Practical reasoning
domain N = 9, 30%
Maleea et al. (2011) Y-60; 24.5% Y-278; 94.2% on HAART 62% with no mental health problems.
230; 71.1% did not meet criteria for any psychiatric diagnosis.
81% with no caregiver reported behavioural problems in the at-risk or clinically signiﬁcant
range.
88% did not report emotional problems in the at-risk or clinically signiﬁcant range.
Mellins et al. (2009) Not given Y-194; 84% on HAART N = 81; 39.3% did not meet criteria for any psychiatric disorders
N = 105; 51% did not meet criteria for anxiety disorder
N = 191; 92.7% did not meet criteria for mood disorder
N = 153; 74.3% did not meet criteria for behavioural disorder
N = 169; 82% did not meet criteria for ADHD
N = 202; 98.1% did not meet criteria for substance abuse
Rice et al. (2012) Y-180; 41% Y-252 HAART, 13 ART (93%) 284; 61% had no language impairment
Serchuck et al. (2010) Not given Y-81% HAART 59% reported no pain in the last 2 months. 72% reported no pain in the last 2 weeks.,
80% did not report pain lasting more than one week.
Thomaidis et al. (2010) Not given Y-11 onHAART and9 onHAART
and AZT. 100% of HIV positive
SDQ results (HIV positive with normal scores)
Emotional HIV without NA—N = 12, 80%, with NA—N = 5, 100%
Conduct HIV without NA—N = 13, 86.7%, with NA—N = 4, 80%
Hyperactivity, HIV without NA—N = 10, 66.7%,with NA—N = 5, 100%
Peer problems HIV without NA—N = 14, 93.3%, with NA—N = 4, 80%
Prosocial,HIV without NA—N = 14, 93.3% with NA—N = 5, 100%
Total score—HIV without NA—N = 11, 73.3%, with NA—N = 5, 100%
IQ (HIV positive with normal scores)
General HIV without NA—N = 6, 40% with NA—N = 0, 0%
Practical IQ score HIV without NA—N = 5, 33.3% with NA—N = 0, 0%
Verbal IQ score HIV without NA—N = 6, 40% with NA—N = 0, 0%
*NA = Neuroimaging abnormalities
Van Rie et al. (2008) Not given N-ART-naive or b1 week
HAART before assessment.
All children (18–72 months) No mental development delay N = 5, 14.3%,; No motor
development delay N = 11, 31.4%
Children 18–29 months; No mental development delay N = 0, 0%
No motor development delay N = 1, 9%
Children 30–72 months—No mental development delay N = 5, 20.8%
No motor development delay N = 10, 41.7%
No language comprehension delay N = 3, 23.1%
No language expression delay N = 2, 15.4%
Van Rie et al. (2009) N Y-71% on HAART Only mean scores given
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in the normal range for the anxiety and social withdrawal scales on
the CBCL. All males were in the normal range for the overall score
and all females were in the normal range for aggression.
4. Discussion
The 2009 review showed the growing evidence on cognitive
challenges in HIV. In contrast the updated review captures the shift of
studies from the USA to sub-Saharan Africa, the deeper understanding
of cognitive challenges and the complexity of effects. Sixty-six percent
of studies were from the USA in 2009 and this has reduced to 43%,
reﬂecting the reality that the majority of HIV positive children live in
Sub-Saharan Africa and the attention which is now being focussed on
this group. Although there is a literature on gender and cognitive
functioning in the non-HIV arena, too few studies analysed their data
by gender to give full insight into gender variation to guide programmes
and interventions.
The studies identiﬁed in the update show more complex design
including a greater array of measures with a broader coverage of
cognitive domains. These serve to initiate insight into a more complex
understanding of cognitive performance, development and behavioural
concepts usually included under the broad scope of cognitive function.
The broad areas of challenge for children with HIV infection are becom-
ing clear. The review describes how children with HIV infection show a
delay in a number of domains. This holds true across various differentcomparison groups. HIV negative children born to HIV positivemothers
provide a comparison group for some studies. This controls for HIV
infection in the household, HIV exposure in utero and even possibly
ART exposure. This data seems to identify the importance of direct
viral implications in cognitive development and a future area of study.
In relation to the behavioural components of child functioning, the
picture is somewhat complex. Although behavioural problems were
noted in some studies, they were not found in all. Indeed in some
(Baker et al., 2012) the asthma group had more social interaction
difﬁculties as it appears that the HIV positive children have beneﬁted
from sustained support. The spotlight, however, may have different
effects. Chernoff et al. (2009) noted that HIV positive children had
equal prevalence of behavioural challenges to comparison children,
but were more likely to be treated with medication or behavioural
interventions. The environment within which the children are raised
seems to be an important factor in the course of their developmental
outcome. This was highlighted in a study by Dobrova-Krol, Bakermans-
Kranenburg, Van IJzendoorn, and Juffer (2010) who cautioned that the
presence of institutionalised rearing was associated with negative
outcomes more so than HIV status. The wide range of economic and
social environments for children may need to be controlled more
carefully in future studies, given the independent contributions of
environment on child outcome. As the vast majority of children
with HIV reside in Africa, clarity is needed about the extent to
which studies from other settings generalise. Cognitive delay risks
may be a compound challenge to children in the HIV era who risk
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independently associated with developmental delay.
More recent studies are providing more detailed explanations and
ways of exploring and predicting cognitive challenges and speciﬁc
deﬁcits. For example Thomaidis et al. (2010) commented on the impor-
tance of neuroimaging abnormalities in outcome and differentiated the
outcomes for those with and without abnormalities. Cognitive perfor-
mance may be affected by multiple variables. Ferguson and Jelsma
(2009) noted that in addition to different outcome scores, children
with HIV also had signiﬁcantlymore hospital admissions, single parents
and differences in housing environments. These intervening variables
may contribute to cognitive development via environmental stimula-
tion and learning opportunity. Serchuck et al. (2010) noted the impor-
tance of pain as a mediator in performance. Thus any study purely
concentrating on cognitive variables may miss such mediators. Nutri-
tion was seen as a factor to be considered indirectly as height and
weight measures interacted with performance (Isaranurug &
Chompikul, 2009). Environment, parenting and stimulation also ap-
peared to be a factor to consider in child cognitive development.
Jelsma et al. (2011) reported on poor stimulation in environments
when comparing both foster care and institutional care for HIV positive
children. Maleea et al. (2011) noted that children with HIV had more
problems than comparison exposed but uninfected children, but report-
ed that caregiver characteristics were associated with higher odds of
problems, including psychiatric disorder, limit setting problems and
health related functional limitations.
More than 2.3 million children younger than 15 years old are
living with HIV, of which 90% are living in Africa (WHO pediatric
adovacy toolkit, 2011). Without access to HIV care and treatment,
every day almost 800 HIV positive children die. Only 28% of children
who require treatment are receiving it compared to 37% of adults. In
some African countries the disparity between children and adults on
treatment is greater (WHO pediatric adovacy toolkit, 2011). In terms
of cognitive performance, there are two ways in which antiretroviral
treatment may work. Firstly, the treatment may stop future infections
preventing less hospitalisation for HIV positive children and therefore
they have increased availability of learning. The second possible way
is that the treatment may reduce viral load directly. In the adult
literature (Best et al., 2009), choice of compounds seems to be important
given differential rates of brain barrier permeation (Koopmans, Ellis,
Best, & Letendre, 2009) found in adult studies, but not yet examined in
children.
In the systematic review antiretroviral treatment should be consid-
ered in terms of its effects and relationship to cognitive performance.
One study pointed out that CD4 count at initiation of treatment was a
predictor of cognitive performance, as was duration of treatment
(Koekkoek et al., 2008). The evidence on the effects of antiretroviral
are mixed. Jelsma et al. (2011) reported that antiretroviral treatment
did not result in restoration of performance. Lowick et al. (2012)
noted a 7.9 fold increase in severe delay in HIV infected children com-
pared to control children. Brackis-Cott et al. (2009) reported that for a
youth sample those taking medication had lower WRAT-3 scores. Of
the six studies that had 10% of the HIV positive or less in the normal
range on at least one measure, two studies samples were 100% antire-
troviral naïve and one did not specify. All HIV positive children in anoth-
er two studies were on treatment. In one study they were on treatment
for a year and in the other they did not specify the length of treatment.
Another study had a sample of 66.6% of HIV positive children on treat-
ment but they also do not specify the length of time on treatment. Clear-
ly such studies are not comparable. Research shows that being on
combination antiretroviral therapy for a year is associated with modest
improvements in neurocognition in particular attention, processing
speed and executive performance (Antinori et al., 2013) thus informa-
tion on initiation and duration of treatment in necessary, as well as
more detail on the type of regimen and those containing protease inhib-
itors. Van Rie et al. (2009) showed the importance of early interventionin children, with the most gains shown in the early presenters. This
study also shows the importance of longer term follow up rather than
cross sectional data in order to understand the course of cognitive de-
velopment. It is unclear in this study which component of the interven-
tion can be linked to the improvements that were seen over time, as
children were provided with treatment for opportunistic infections, ac-
cess to nutritional programmes and highly active antiretroviral
treatment as appropriate. However, it is also important to look at loss
to follow up, as the longer term studies may lose the most severely ill
children and thus skew the data.
The quality of the data severely hampers clear insight into the true
prevalence of delay, the causal pathways and the options for remedia-
tion. Multiple measures are used across a wide age span and thus
meta-analysis and data pooling of any sort is difﬁcult. Even within the
same measures, different studies use the data in different ways—such
as absolute scores, or percentage and proportionwith severe delay. Fur-
thermorewhen standardised scales are translated or adapted they need
to be revalidated—few studies report on such attention to detail. Few
studies are able to control for many of the variables that may also con-
tribute to the presence and course of delay over time. Longitudinal stud-
ies are rare and cross sectional studies have limitations. Some studies
(example Van Rie et al., 2008) look at different age cohorts and ﬁnd
that “young HIV infected children performed worse”. This may be a
sampling issue where children with severe disease, in the absence of
treatment, do not survive into the older age groups and this dispropor-
tionately affects the range of scores among surviving children. Van Rie
et al. (2008) found the proportion of children with missed follow up
visits was higher among the younger than older children. In particular
in the infected children, only 5 out of the 11 younger children attended
the 2nd or 3rd follow-up visit whereas 22 out of 24 of the older children
attended the follow up. Themajority of missed visits were due to 7 chil-
drenwho died. Those who aremore likely to survivemay have the least
effects. Ceiling effects may have also been present. For example, the
study by Ananworanich et al. (2008) noted high levels of behavioural
problems among all groups in their study which compared HIV positive
children with those diagnosed with haematological/oncological disor-
ders. Exposure to antiretroviral treatment may differ with the HIV pos-
itive children less likely to be exposed to maternal HAART, than the
uninfected HIV exposed infants. Other treatment factors may also inter-
act with cognitive performance (such as medication for psychiatric or
other health conditions). Thus claims about group improvements over
time should be viewed with caution and only after data is adjusted for
those who do not survive. Within all the studies, the use of group
mean scores make it difﬁcult to know if all the children are performing
under a certain level, or if a small subgroup of children are performing
particularly poorly and affecting the total mean. This detailed informa-
tion would speciﬁcally assist in targeting care, and appreciating if a
large number of children needed help with relatively small problems,
or if a smaller group of children needed intervention with widespread
severe problems (or both).
Policy for children in this area is urgently required. For adequate and
appropriate HIVmanagement, it is vital to test and establish theHIV sta-
tus of each child. In 2009, an estimated 1.4 million HIV exposed infants
were born but only 6% received early infant diagnosis services. Infants
who are tested may not receive their results and only a third who test
positive initiate ART (WHO pediatric adovacy toolkit, 2011). Treatment
rollout to all children is urgently needed. Information on the
neuroproperties of treatment on children is also required. In adults,
ART distribution and effectiveness in the Central Nervous System
(CNS) varies substantially between different compounds and individ-
uals. ART that has better neuroeffectiveness may improve or prevent
HAND (Letendre et al., 2008). Guidelines in this area need to include
speciﬁc instructions on children.
Children have the right to education and this data clearly indicates a
need for more special education provision for HIV positive children.
Studies do show that targeted interventions are available to enhance
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With treatment HIV Positive children are growing up and reaching
adolescence. If their decision-making skills are compromised HIV
management and risk reduction may be hampered if they face spe-
ciﬁc challenges with partnership and risk negotiation, HIV status dis-
closure and risk behaviour reduction. Interventions to improve
cognitive skills is of beneﬁt in its own right and additionally may
help with many of the decision making skills needed for safe sex
and behavioural change that play a role in spreading the infection.
Cognitive development, overall, is a neglected area of study and pro-
vision. Baseline and repeated measures are not routinely collected
and repeated for children. Clinic staff should be trained to respond
to a child with cognitive deﬁcits. The area has moved forward for
adults, but assessment and treatment for children lags behind. The
review has identiﬁed a need for researchers to harmonise measures
to improve research in this area.
The review highlights the need to examine HIV positive children
who do not have any cognitive deﬁcits to understand predictors of
performance and to guide interventions and prevention initiatives.
If we are able to identify these children, is it possible to transfer the
resilience skills to others? Of the six studies which included 10% or
less of HIV children without delay, four were in sub-Saharan Africa
(3 in South Africa) of which two included children who were not re-
ceiving antiretroviral treatment. Of the nine studies with at least one
measure, where 80% or more children had no deﬁcits only one was
from sub-Saharan Africa and six (66%) almost exclusively USA
based. Three studies provided sub domain analysis and showed
that on at least one measure 10% or less or the sample scored in the
“normal” ranges. This supports the possibility that cognitive deﬁcits
occur in certain sub-domains but not all—particular appropriate for
measures of motor and mental development. IQ (general, practical
and verbal)was found to be affected in childrenwho have neuroimaging
abnormalities. There is a notable absence of information for the youngest
age ranges.
5. Conclusion
Despite the shortcomings of the data, the challenges in synthesising
the studies and the broad umbrella of concepts included under the
heading of cognitive and behavioural performance, this updated review
shows clear on-going evidence that children with HIV may well have
special educational needs and face the prospect of cognitive delay in
some domains of functioning. These results are now well established
and they suggest that centres should be considering routine cognitive
monitoring for children from an early age and on a regular basis and
the provision of interventions to ameliorate or cater for the cognitive
function needs of children. Early child development and stimulation
may be particularly relevant for young children, despite the paucity of
data for the youngest age groups. For older children, school provision
and adaptations for special needs requirements should be prioritised
to accommodate their needs. Future studies ought to untangle the
complex potential causal chains and pathways which contribute to the
ﬁndings. Well validated scales and agreed measures are overdue. Inter-
vention studies are urgently needed and learning from the non HIV
child developmental delay literature should serve to inform possible
remedial or supportive provision, treatment decisions, compound
choices and special educational provision to overcome or accommodate
such cognitive delay.
Appendix AA.1. PsycINFO search
1. Exp HIV/(27361)
2. (HIV or human immunodeﬁciency syndrome or AIDS or acquired im-
munodeﬁciency virus).mp. [mp= title, abstract, headingword, table
of contents, key concepts, original title, tests & measures] (47730)
3. 2 or 4 (42483)4. (child or minor or infant or preteen or baby or newborn or
neonate).mp. [mp= title, abstract, headingword, table of contents,
key concepts, original title, tests & measures] (195748)
5. exp Early Childhood Development/(17861)
6. exp Infant Development/(11423)
7. exp Cognitive Development/(28953)
8. exp Cognitive Ability/(48562)
9. exp Cognitive Impairment/(18708)
10. (cognitive development or development or neurological functioning
or intellectual or learning or language or memory).mp. [mp = title,
abstract, headingword, table of contents, key concepts, original title,
tests & measures] (670258)
11. exp AIDS Dementia Complex/(120)
12. (child behaviour or child behavior).mp. [mp = title, abstract,
heading word, table of contents, key concepts, original title, tests
& measures] (12024)
13. exp Psychosocial Development/(18755)
14. exp Emotional Development/(3973)
15. exp Physical Development/(18931)
16. (social development or physical development or emotional
development).mp. [mp = title, abstract, heading word, table of
contents, key concepts, original title, tests & measures] (10074)
17. 9 or 11 or 13 or 15 or 17 or 19 or 21 or 23 or 25 or 27 or 29 or 31 or
33 (713624)
18. (control or comparison).mp. [mp = title, abstract, heading word,
table of contents, key concepts, original title, tests & measures]
(298776)
19. comparative.mp. [mp = title, abstract, heading word, table of
contents, key concepts, original title, tests & measures] (25922)
20. exp Experiment Controls/(405)
21. exp Intervention/(46460)
22. (intervention or time-series or case-control or “before and
after”).mp. [mp = title, abstract, heading word, table of contents,
key concepts, original title, tests & measures] (153646)
23. 36 or 38 or 40 or 42 or 44 (437797)
24. 5 and 7 and 34 and 45 (322)
A.2. Medline search
1. HIV infections/(127971)
2. (HIV or human immunodeﬁciency virus or AIDS or acquired immu-
nodeﬁciency virus).mp. [mp= title, abstract, original title, name of
substance word, subject heading word, keyword heading word,
protocol supplementary concept, rare disease supplementary con-
cept, unique identiﬁer] (284755)
3. 2 or 4 (284755)
4. Child/(744764)
5. Infant/(332968)
6. (child or minor or infant or preteen or baby or newborn or
neonate).mp. [mp= title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol sup-
plementary concept, rare disease supplementary concept, unique
identiﬁer] (1344606)
7. 7 or 9 or 11 (1344606)
8. Delirium, Dementia, Amnestic, Cognitive Disorders/(3312)
9. (cognitive development or development or neurological functioning
or intellectual or learning or language or memory).mp. [mp = title,
abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept,
rare disease supplementary concept, unique identiﬁer] (1400887)
10. (child behaviour or child behavior).mp. [mp= title, abstract, origi-
nal title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept, rare disease
supplementary concept, unique identiﬁer] (18334)
11. (social development or physical development or emotional
development).mp. [mp = title, abstract, original title, name of
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protocol supplementary concept, rare disease supplementary
concept, unique identiﬁer] (3277)
12. Child Development/(18348)
13. 14 or 16 or 18 or 20 or 22 (1415171)
14. Control Groups/(1199)
15. Comparative Effectiveness Research/(904)
16. Intervention Studies/(5598)
17. (intervention or time series or case-control or “before and
after”).mp. [mp = title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol sup-
plementary concept, rare disease supplementary concept, unique
identiﬁer] (570287)
18. (control or comparison).mp. [mp = title, abstract, original title,
name of substance word, subject heading word, keyword heading
word, protocol supplementary concept, rare disease supplementary
concept, unique identiﬁer] (1898112)
19. comparative.mp. [mp = title, abstract, original title, name of sub-
stance word, subject heading word, keyword heading word, proto-
col supplementary concept, rare disease supplementary concept,
unique identiﬁer] (1232605)
20. 25 or 27 or 29 or 31 or 33 or 35 (3036475)
21. 5 and 12 and 23 and 36 (1417)References
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